Free Trial
OTCMKTS:SPHRY

Starpharma (SPHRY) Stock Price, News & Analysis

Starpharma logo
$0.75 0.00 (0.00%)
(As of 11/20/2024 ET)

About Starpharma Stock (OTCMKTS:SPHRY)

Key Stats

Today's Range
$0.75
$0.75
50-Day Range
$0.54
$0.76
52-Week Range
$0.52
$1.33
Volume
3,200 shs
Average Volume
4,798 shs
Market Capitalization
$31.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Receive SPHRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter.

SPHRY Stock News Headlines

Starpharma Highlights Dendrimer Technology at Healthcare Conference
Starpharma Showcases Dendrimer Innovations at Microcap Conference
Trump said you could learn something from this man
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
Starpharma Holdings Ltd. ADR
Starpharma's VivaGel Approval Denied By FDA
Starpharma Holdings Ltd SPL
Starpharma Holdings Limited
See More Headlines

SPHRY Stock Analysis - Frequently Asked Questions

Starpharma's stock was trading at $1.2440 at the start of the year. Since then, SPHRY shares have decreased by 39.7% and is now trading at $0.75.
View the best growth stocks for 2024 here
.

Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
11/21/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
OTCMKTS:SPHRY
CIK
N/A
Employees
45
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.40 million
Book Value
$0.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$31.36 million
Optionable
Not Optionable
Beta
1.06
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:SPHRY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners